◎ Sugi Atlas

Atlas / Drug / Flunitrazepam

Flunitrazepam

drug
On this page

Also known as N05CD03RO-54200Rohypnol

Summary

Flunitrazepam (CHEMBL13280) is an approved small-molecule GABAA receptor agonist (ATC N05CD03) targeting GABRA1, GABRA2, and GABRA3.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: N05CD03
  • Targets: 4 (GABRA1, GABRA2, GABRA3…)
  • Chemistry: 313.28 Da · C16H12FN3O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL13280
NameFlunitrazepam
TypeSmall molecule
Max phase4
FDA approvedno
PubChem CID3380
ChEBICHEBI:31622
ATCN05CD03
Molecular formulaC16H12FN3O3
Molecular weight313.28
InChIKeyPPTYJKAXVCCBDU-UHFFFAOYSA-N

SMILES: CN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3F

IUPAC name: 5-(2-fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one

ChEBI definition: A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2’. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.

Pharmacological roles (ChEBI): sedative, GABAA receptor agonist, anxiolytic drug.

Also known as: Flunitrazepam, N05CD03, RO-54200, Rohypnol, flunitrazepam, FLUNITRAZEPAM

Patent coverage: 3,096 distinct patent families (11,549 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 11,270 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
GABRA1GABAA receptor α1 subunitPositive8.280%P14867
GABRA2GABAA receptor α2 subunitPositive8.280%P47869
GABRA3GABAA receptor α3 subunitPositive7.80%P34903
GABRA5GABAA receptor α5 subunitPositive8.260.9%P31644

Broader ChEMBL bioactivity targets: 16 (assay-derived). Sample: GABA-A receptor; anion channel, Gamma-aminobutyric acid receptor subunit alpha-1, GABA-A receptor; alpha-3/beta-3/gamma-2, GABA-A receptor; alpha-1/beta-3/gamma-2, GABA-A receptor; alpha-5/beta-3/gamma-2, GABA-A receptor; alpha-2/beta-3/gamma-2, GABA-A receptor; alpha-1/beta-2/gamma-2, GABA A receptor alpha-3/beta-2/gamma-2, GABA A receptor alpha-2/beta-2/gamma-2, Kappa-type opioid receptor.

Bioactivity

ChEMBL activities: 25 potent at pChembl ≥ 5 of 28 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
GABRG28.96Ki1.1nMCHEMBL_ACT_431829
GABRA18.85EC501.4nMCHEMBL_ACT_2187197
O090288.82IC501.5nMCHEMBL_ACT_1276651
O090288.77IC501.7nMCHEMBL_ACT_1009343
O090288.77IC501.7nMCHEMBL_ACT_996912
GABRG28.68Ki2.1nMCHEMBL_ACT_24843286
GABRG28.68Ki2.1nMCHEMBL_ACT_622023
GABRG28.68Ki2.1nMCHEMBL_ACT_891082
GABRA18.66Ki2.2nMCHEMBL_ACT_24843223
GABRA18.66Ki2.2nMCHEMBL_ACT_622020
GABRA18.66Ki2.2nMCHEMBL_ACT_891079
GABRG28.6Ki2.5nMCHEMBL_ACT_24843244
GABRG28.6Ki2.5nMCHEMBL_ACT_622021
GABRG28.6Ki2.5nMCHEMBL_ACT_891080
GABRA58.52Kd3nMCHEMBL_ACT_2461354
O090288.52IC503nMCHEMBL_ACT_790071
GABRA18.41Ki3.9nMCHEMBL_ACT_431828
GABRA18.35Kd4.5nMCHEMBL_ACT_2461333
GABRG28.35Ki4.5nMCHEMBL_ACT_24843265
GABRG28.35Ki4.5nMCHEMBL_ACT_622022
GABRG28.35Ki4.5nMCHEMBL_ACT_891081
P628138.26AC505.5nMCHEMBL_ACT_25130810
GABRG28.23Ki5.9nMCHEMBL_ACT_431830
O090288.1IC508nMCHEMBL_ACT_790072
OPRK15.2AC506387nMCHEMBL_ACT_25129629

Target pathways

Aggregated over 4 target gene(s): GABRA1, GABRA2, GABRA3, GABRA5.

Top Reactome pathways

2 total, by targets touching each:

PathwayTargetsGenes
GABA receptor activation4GABRA1, GABRA2, GABRA3, GABRA5
Signaling by ERBB41GABRA1

Dominant GO biological processes

GO termTargets
gamma-aminobutyric acid signaling pathway4
synaptic transmission, GABAergic4
chloride transmembrane transport4
inhibitory synapse assembly4
monoatomic ion transport4
chloride transport4
monoatomic ion transmembrane transport4
regulation of postsynaptic membrane potential4
regulation of presynaptic membrane potential2
behavioral fear response1
signal transduction1
associative learning1
inner ear receptor cell development1
innervation1
cochlea development1

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

75 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
ALPRAZOLAMChEMBLPhase 4 (approved)GABRA1, GABRA2, GABRA3, GABRA5
APALUTAMIDEChEMBLPhase 4 (approved)GABRA1, GABRA2, GABRA3, GABRA5
BREXANOLONEChEMBLPhase 4 (approved)GABRA1, GABRA2, GABRA3, GABRA5
CHLORDIAZEPOXIDEChEMBLPhase 4 (approved)GABRA1, GABRA2, GABRA3, GABRA5
CLONAZEPAMChEMBLPhase 4 (approved)GABRA1, GABRA2, GABRA3, GABRA5
DIAZEPAMChEMBLPhase 4 (approved)GABRA1, GABRA2, GABRA3, GABRA5
ENZALUTAMIDEChEMBLPhase 4 (approved)GABRA1, GABRA2, GABRA3, GABRA5
FLUMAZENILChEMBLPhase 4 (approved)GABRA1, GABRA2, GABRA3, GABRA5
GANAXOLONEChEMBLPhase 4 (approved)GABRA1, GABRA2, GABRA3, GABRA5
LIOTHYRONINEChEMBLPhase 4 (approved)GABRA1, GABRA2, GABRA3, GABRA5
PROPOFOLChEMBLPhase 4 (approved)GABRA1, GABRA2, GABRA3, GABRA5
TRIAZOLAMChEMBLPhase 4 (approved)GABRA1, GABRA2, GABRA3, GABRA5
ALFAXALONEChEMBL + PubChemPhase 2 (approved)GABRA1, GABRA2, GABRA3, GABRA5
ABECARNILChEMBLPhase 2GABRA1, GABRA2, GABRA3, GABRA5
AZD7325ChEMBLPhase 2GABRA1, GABRA2, GABRA3, GABRA5
BAICALEINChEMBLPhase 2GABRA1, GABRA2, GABRA3, GABRA5
BASMISANILChEMBLPhase 2GABRA1, GABRA2, GABRA3, GABRA5
BRETAZENILChEMBLPhase 2GABRA1, GABRA2, GABRA3, GABRA5
DELORAZEPAMChEMBLPhase 2GABRA1, GABRA2, GABRA3, GABRA5
FLAVONEChEMBLPhase 2GABRA1, GABRA2, GABRA3, GABRA5
MK-0777ChEMBLPhase 2GABRA1, GABRA2, GABRA3, GABRA5
PROGABIDEChEMBLPhase 2GABRA1, GABRA2, GABRA3, GABRA5
ESZOPICLONEChEMBLPhase 4 (approved)GABRA1, GABRA2, GABRA3
ZOLPIDEMChEMBLPhase 4 (approved)GABRA1, GABRA2, GABRA3
DARIGABATChEMBLPhase 2GABRA1, GABRA3, GABRA5
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)GABRA1, GABRA2
ASENAPINEChEMBLPhase 4 (approved)GABRA1, GABRA2
AZELASTINEChEMBLPhase 4 (approved)GABRA1, GABRA2
BENPERIDOLChEMBLPhase 4 (approved)GABRA1, GABRA2
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)GABRA1, GABRA2
CHLORAMBUCILChEMBLPhase 4 (approved)GABRA1, GABRA2
CLOZAPINEChEMBLPhase 4 (approved)GABRA1, GABRA2
EPINASTINEChEMBLPhase 4 (approved)GABRA1, GABRA2
ETOMIDATEChEMBLPhase 4 (approved)GABRA1, GABRA2
GLAFENINEChEMBLPhase 4 (approved)GABRA1, GABRA2
SIMVASTATINChEMBLPhase 4 (approved)GABRA1, GABRA2
TIPRANAVIRChEMBLPhase 4 (approved)GABRA1, GABRA2
TROGLITAZONEChEMBLPhase 4 (approved)GABRA1, GABRA2
ZALEPLONChEMBLPhase 4 (approved)GABRA1, GABRA2
SURAMINChEMBLPhase 3GABRA1, GABRA2
TIRATRICOLChEMBLPhase 3GABRA1, GABRA2
PANADIPLONChEMBLPhase 2GABRA1, GABRA3
SARIPIDEMChEMBLPhase 2GABRA1, GABRA5
ZOTEPINEChEMBLPhase 2GABRA1, GABRA2
AfatinibPubChemApprovedGABRA1, GABRA2
ApixabanPubChemApprovedGABRA1, GABRA2
BinimetinibPubChemApprovedGABRA1, GABRA2
chenodiolPubChemApprovedGABRA1, GABRA2
FulvestrantPubChemApprovedGABRA1, GABRA2
gentian violetPubChemApprovedGABRA1, GABRA2
ImipenemPubChemApprovedGABRA1, GABRA2
LactulosePubChemApprovedGABRA1, GABRA2
levocarnitinePubChemApprovedGABRA1, GABRA2
podofiloxPubChemApprovedGABRA1, GABRA2
Propylene GlycolPubChemApprovedGABRA1, GABRA2
PyrazinamidePubChemApprovedGABRA1, GABRA2
PyridoxinePubChemApprovedGABRA1, GABRA2
RiociguatPubChemApprovedGABRA1, GABRA2
saxagliptinPubChemApprovedGABRA1, GABRA2
ThiaminePubChemApprovedGABRA1, GABRA2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 27

This page pulls from 27 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot